0922 ESMO roundup
BioCentury & Getty Images

Product Development

Immunomedics data point to Trodelvy’s $21B potential

Plus ESMO data from Amgen, J&J, AstraZeneca and BMS

Sep 23, 2020 | 12:38 AM GMT

New data from Immunomedics suggest its antibody-drug conjugate Trodelvy is on track for the label expansions worked into Gilead’s $21 billion takeout price for the biotech. At the European Society for Clinical Oncology Virtual Congress, the company shared a pair of posters that provide confirmatory data for Trodelvy in triple-negative breast cancer following its conditional approval in April, and make the case for

Read the full 910 word article

How to gain access

Continue reading with a
two-week free trial.